A Comparison of Three Fibrinolytic Agents in Prevention of Intra-Abdominal Adhesions

Topal, Ersun; Öztürk, Ersin; Şen, Gürol; Yerci, Ömer; Yılmazlar, Tuncay

doi:10.1080/00015458.2010.11680569

Cited by 20 publications

(18 citation statements)

References 10 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are consistent with another study showing that recombinant APC can inhibit intraperitoneal adhesions in a rat model. 34 However, this previous study did not provide any insight into the mechanisms through which APC inhibits peritoneal adhesions.…”

Section: Discussionmentioning

confidence: 98%

Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation

Dinarvand

Hassanian

Weiler

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation

Dinarvand

Hassanian

Weiler

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…Ces membranes peuvent servir à relarguer des anti-inflammatoires [158,159] voire même des molécules antinéoplasiques [160,161]. L'utilisation d'agent régulant la réponse inflammatoire comme des anticorps anti-TGF␤1 [162], de la vitamine E [163], des fibrinolytiques [164,165] ou encore des molécules antiprolifératives [166][167][168] ont également montré une réduction des adhérences postopératoires.…”

Section: Les Voies De Développementunclassified

Prévention et traitement des synéchies endo-utérines : revue de la littérature

Warembourg

Huberlant

Garric

et al. 2015

Journal de Gynécologie Obstétrique et Biologie de la Reproducti

View full text Add to dashboard Cite

“…APC has anticoagulant, fibrinolytic, and anti-inflammatory properties [6,7,8]. Moreover, since APC has been shown to be safe in patients with severe sepsis with a suggestion of antimicrobial effects [9], we hypothesized that this drug may be well suited for HD patients with high degrees of baseline inflammation.…”

Section: Introductionmentioning

confidence: 99%

Safety and Dose-Finding Study of Activated Protein C (Drotrecogin Alfa Activated) as an Anticoagulant in End-Stage Renal Disease Patients Treated with Hemodialysis

et al. 2014

View full text Add to dashboard Cite

Background/Aims: End-stage renal disease (ESRD) patients treated with hemodialysis (HD) experience a high risk of death. ESRD patients with elevated levels of pro-inflammatory cytokines are at increased risk of death from cardiovascular events and infection. HD is often facilitated by the use of an anticoagulant. We hypothesized that the use of an anticoagulant that also possessed anti-inflammatory qualities without significant immunosuppressive effects may reduce the risk of death. In this pilot study, we sought to determine the optimal dose of activated protein C (APC) to achieve adequate regional anticoagulation for HD and determine if the drug can be safely used in ESRD patients treated with HD. Methods: Twelve stable HD patients were enrolled into this safety and dose-finding study. Varying doses of APC were administered in place of usual heparin at varying doses to determine the range of APC that can be used for extracorporeal circuit anticoagulation. Partial thromboplastin time was assessed at fixed intervals during the HD treatment. Results: The average age of study patients was 49 ± 12 years. 75% of patients were African-American and 66.7% were male. The optimal dose of APC to induce adequate anticoagulation was 24-30 μg/kg/h. No patients experienced any serious adverse events. One patient had their infusion stopped early due to refractory intradialytic hypertension. Conclusions: For ESRD patients undergoing HD, an initial starting dose of 24-30 μg/kg/h achieves a target partial thromboplastin time that should be adequate for circuit anticoagulation. This dose appears safe and was well tolerated.

show abstract

A Comparison of Three Fibrinolytic Agents in Prevention of Intra-Abdominal Adhesions

Abstract: All three agents were effective in preventing adhesions when compared to the control group. Nevertheless, ADA seemed the most effective except when considering clinical applicability, in which case FS seemed to offer the greatest advantage.

Cited by 20 publications

References 10 publications

Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation

Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation

Prévention et traitement des synéchies endo-utérines : revue de la littérature

Safety and Dose-Finding Study of Activated Protein C (Drotrecogin Alfa Activated) as an Anticoagulant in End-Stage Renal Disease Patients Treated with Hemodialysis

Contact Info

Product

Resources

About